title: Gene expression profiling distinguishes JAK2V617F-negative from JAK2V617F-positive patients in essential thrombocythemia.
abstract: To explore the gene expression signature in essential thrombocythemia (ET) patients in relation to JAK2V617F mutational status, expression profiling in circulating granulocytes was performed. Twenty ET were studied by microarray analysis and the results were confirmed by real-time quantitative RT-PCR in 40 ET patients, not receiving cytoreductive treatment. A heterogeneous molecular signature characterized by two main gene expression patterns was found: one with an upregulation of inflammatory genes related to neutrophil activation and thrombosis, and the other with significantly lower expression of these genes. Supervised clustering analysis showed 30 genes differentially expressed between JAK2V617F-negative and JAK2V617F-positive ET patients. Among the JAK2V617F-negative, a set of 14 genes (CISH, C13orf18, CCL3, PIM1, MAFF, SOCS3, ID2, GADD45B, KLF5, TNF, LAMB3, HRH4, TAGAP and TRIB1) showed an abnormal expression pattern. In this group of patients, CISH, SOCS2, SOCS3 and PIM1 genes, all involved in JAK-STAT signalling pathway, presented a lower expression. A two-gene predictor model was built comprising FOSB and CISH genes, which were the best discriminators of JAK2V617F status. In conclusion, JAK2V617F-negative ET patients present a characteristic gene expression profile, different from JAK2V617F-positive patients. Other pathways, besides JAK-STAT, might be implicated in the pathophysiology of JAK2V617F-negative ET patients.
authors.affiliation: Laboratori de Citogenètica i Biologia Molecular, Servei de Patologia. Hospital del Mar, IMAS, Barcelona, Spain.
authors.forename: E
authors.initials: E
authors.lastname: Puigdecanet
authors.forename: B
authors.initials: B
authors.lastname: Espinet
authors.forename: J J
authors.initials: JJ
authors.lastname: Lozano
authors.forename: L
authors.initials: L
authors.lastname: Sumoy
authors.forename: B
authors.initials: B
authors.lastname: Bellosillo
authors.forename: L
authors.initials: L
authors.lastname: Arenillas
authors.forename: A
authors.initials: A
authors.lastname: Alvarez-Larrán
authors.forename: F
authors.initials: F
authors.lastname: Solé
authors.forename: S
authors.initials: S
authors.lastname: Serrano
authors.forename: C
authors.initials: C
authors.lastname: Besses
authors.forename: L
authors.initials: L
authors.lastname: Florensa
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D020133:Reverse Transcriptase Polymerase Chain Reaction; D050791:STAT Transcription Factors / Q000502:physiology; D015398:Signal Transduction; D013920:Thrombocythemia, Essential / Q000235:genetics*
chemical_list: D050791:STAT Transcription Factors; C507924:JAK2 protein, human; D053614:Janus Kinase 2